Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Luveltamab tazevibulin - Sutro Biopharma

Next Previous
X
Search
Drug Profile

Luveltamab tazevibulin - Sutro Biopharma

Alternative Names: anti-FolRa ADC STRO-002; anti-FolRalpha ADC STRO-002; FolR-alpha-ADC-Sutro-Biopharma; Luvelta; STRO-002

Latest Information Update: 20 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sutro Biopharma
  • Developer Gynecologic Oncology Group; Sutro Biopharma; Tasly Biopharmaceuticals
  • Class Amides; Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Indoles
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Ovarian cancer
  • Phase II Non-small cell lung cancer
  • Phase I/II Solid tumours
  • Phase I Endometrial cancer
  • Clinical Phase Unknown Acute myeloid leukaemia
  • No development reported Fallopian tube cancer; Peritoneal cancer

Most Recent Events

  • 14 Sep 2024 Efficacy and adverse events data from a phase Ib trial in Ovarian cancer released by Sutro Biopharma
  • 22 Aug 2024 Sutro Biopharma plans the phase II/III REFRaME-P1 trial in Acute myeloid leukemia (In children) in the second half of 2024
  • 21 Aug 2024 Phase-II clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV), (NCT06555263)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top